Antibodies to the conserved region of the M protein and a streptococcal superantigen cooperatively resolve toxic shock-like syndrome in HLA-humanized mice.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
09 2019
Historique:
received: 11 03 2019
accepted: 07 08 2019
entrez: 14 9 2019
pubmed: 14 9 2019
medline: 15 5 2020
Statut: epublish

Résumé

Invasive streptococcal disease (ISD) and toxic shock syndrome (STSS) result in over 160,000 deaths each year. We modelled these in HLA-transgenic mice infected with a clinically lethal isolate expressing Streptococcal pyrogenic exotoxin (Spe) C and demonstrate that both SpeC and streptococcal M protein, acting cooperatively, are required for disease. Vaccination with a conserved M protein peptide, J8, protects against STSS by causing a dramatic reduction in bacterial burden associated with the absence of SpeC and inflammatory cytokines in the blood. Furthermore, passive immunotherapy with antibodies to J8 quickly resolves established disease by clearing the infection and ablating the inflammatory activity of the M protein, which is further enhanced by addition of SpeC antibodies. Analysis of 77 recent isolates of

Identifiants

pubmed: 31517054
doi: 10.1126/sciadv.aax3013
pii: aax3013
pmc: PMC6726444
doi:

Substances chimiques

Antibodies, Bacterial 0
Antigens, Bacterial 0
Bacterial Outer Membrane Proteins 0
Bacterial Proteins 0
Carrier Proteins 0
Exotoxins 0
HLA Antigens 0
Superantigens 0
erythrogenic toxin 0
streptococcal M protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

eaax3013

Références

J Immunol. 2002 Mar 15;168(6):3050-6
pubmed: 11884478
BMC Res Notes. 2014 Apr 12;7:233
pubmed: 24725742
Clin Infect Dis. 2003 Aug 1;37(3):333-40
pubmed: 12884156
J Immunol. 2000 Aug 15;165(4):2306-12
pubmed: 10925320
Clin Exp Immunol. 2005 Oct;142(1):1-11
pubmed: 16178850
Cell Microbiol. 2006 Feb;8(2):257-66
pubmed: 16441436
Sci Rep. 2016 Dec 15;6:39274
pubmed: 27976706
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10226-10231
pubmed: 28794279
J Immunol. 1993 Aug 1;151(3):1419-29
pubmed: 8335938
PLoS Pathog. 2014 May 29;10(5):e1004155
pubmed: 24875883
J Exp Med. 1990 Jul 1;172(1):359-62
pubmed: 2358781
J Immunol. 2006 Jul 15;177(2):1221-8
pubmed: 16818781
Infect Immun. 1993 Apr;61(4):1194-201
pubmed: 8454323
Drugs. 2012 Jun 18;72(9):1213-27
pubmed: 22686614
Open Forum Infect Dis. 2018 Jul 20;5(8):ofy177
pubmed: 30109241
J Clin Microbiol. 2005 Apr;43(4):1789-96
pubmed: 15815000
Expert Rev Vaccines. 2015;14(11):1459-70
pubmed: 26485214
J Antimicrob Chemother. 2006 Jul;58(1):117-24
pubmed: 16670109
Adv Exp Med Biol. 2011;715:197-211
pubmed: 21557065
Hum Vaccin Immunother. 2013 Mar;9(3):488-96
pubmed: 23249976
J Infect. 2019 May;78(5):358-363
pubmed: 30796950
Res Microbiol. 2005 May;156(4):575-82
pubmed: 15862457
Infect Immun. 2000 Sep;68(9):5011-7
pubmed: 10948118
J Clin Microbiol. 2009 Aug;47(8):2502-9
pubmed: 19515838
J Immunol. 2007 Mar 1;178(5):3076-83
pubmed: 17312154
Emerg Infect Dis. 2008 Feb;14(2):202-9
pubmed: 18258111
J Infect Dis. 2003 May 15;187(10):1598-608
pubmed: 12721940
PLoS One. 2018 Jul 2;13(7):e0198658
pubmed: 29965967
Clin Infect Dis. 2007 Aug 15;45(4):450-8
pubmed: 17638193
NPJ Vaccines. 2018 Apr 26;3:15
pubmed: 29736269
J Biol Chem. 2006 Feb 10;281(6):3217-26
pubmed: 16319056
Mol Gen Genet. 1988 Apr;212(1):66-70
pubmed: 2836707
Annu Rev Microbiol. 2001;55:77-104
pubmed: 11544350
J Infect Dis. 2001 Jul 15;184(2):166-73
pubmed: 11424013
Cell Microbiol. 2008 Feb;10(2):404-14
pubmed: 17900297
BMC Infect Dis. 2014 May 29;14:294
pubmed: 24885209
Clin Infect Dis. 2014 Sep 15;59(6):851-7
pubmed: 24928291
J Immunol. 2016 Apr 15;196(8):3364-74
pubmed: 26969753
Emerg Infect Dis. 2003 Oct;9(10):1211-8
pubmed: 14609454
Sci Transl Med. 2019 Feb 6;11(478):
pubmed: 30728285
J Immunol. 2015 Jun 15;194(12):5915-25
pubmed: 25980008

Auteurs

Manisha Pandey (M)

Institute for Glycomics, Griffith University, Gold Coast, Australia.

Ainslie Calcutt (A)

Institute for Glycomics, Griffith University, Gold Coast, Australia.

Victoria Ozberk (V)

Institute for Glycomics, Griffith University, Gold Coast, Australia.

Zhenjun Chen (Z)

Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.

Matthew Croxen (M)

Division of Diagnostic and Applied Microbiology, Department of Laboratory Medicine and Pathology, University of Alberta and ProvLab, Edmonton, Canada.

Jessica Powell (J)

Institute for Glycomics, Griffith University, Gold Coast, Australia.

Emma Langshaw (E)

Institute for Glycomics, Griffith University, Gold Coast, Australia.

Jamie-Lee Mills (JL)

Institute for Glycomics, Griffith University, Gold Coast, Australia.

Freda E-C Jen (FE)

Institute for Glycomics, Griffith University, Gold Coast, Australia.

James McCluskey (J)

Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.

Jenny Robson (J)

Sullivan and Nicolaides Pathology, Brisbane, Australia.

Gregory J Tyrrell (GJ)

Division of Diagnostic and Applied Microbiology, Department of Laboratory Medicine and Pathology, University of Alberta and ProvLab, Edmonton, Canada.

Michael F Good (MF)

Institute for Glycomics, Griffith University, Gold Coast, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH